Incyte (INCY) Competitors $85.38 -1.79 (-2.05%) Closing price 04:00 PM EasternExtended Trading$86.34 +0.97 (+1.13%) As of 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INCY vs. ABBV, REGN, ALNY, BIIB, UTHR, NBIX, EXEL, BMRN, IONS, and EXASShould you be buying Incyte stock or one of its competitors? The main competitors of Incyte include AbbVie (ABBV), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Ionis Pharmaceuticals (IONS), and Exact Sciences (EXAS). These companies are all part of the "medical" sector. Incyte vs. Its Competitors AbbVie Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen United Therapeutics Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Ionis Pharmaceuticals Exact Sciences AbbVie (NYSE:ABBV) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability. Do analysts prefer ABBV or INCY? AbbVie presently has a consensus target price of $229.14, suggesting a potential downside of 0.92%. Incyte has a consensus target price of $83.64, suggesting a potential downside of 2.03%. Given AbbVie's stronger consensus rating and higher possible upside, equities analysts clearly believe AbbVie is more favorable than Incyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AbbVie 0 Sell rating(s) 9 Hold rating(s) 15 Buy rating(s) 4 Strong Buy rating(s) 2.82Incyte 1 Sell rating(s) 12 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.22 Does the media prefer ABBV or INCY? In the previous week, AbbVie had 111 more articles in the media than Incyte. MarketBeat recorded 129 mentions for AbbVie and 18 mentions for Incyte. AbbVie's average media sentiment score of 1.13 beat Incyte's score of 0.95 indicating that AbbVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 84 Very Positive mention(s) 15 Positive mention(s) 22 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 8 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation and earnings, ABBV or INCY? AbbVie has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbbVie$56.33B7.25$4.28B$2.10110.12Incyte$4.24B3.93$32.62M$4.4019.40 Which has more risk & volatility, ABBV or INCY? AbbVie has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Incyte has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Is ABBV or INCY more profitable? Incyte has a net margin of 18.99% compared to AbbVie's net margin of 6.45%. AbbVie's return on equity of 699.66% beat Incyte's return on equity.Company Net Margins Return on Equity Return on Assets AbbVie6.45% 699.66% 13.64% Incyte 18.99%21.99%14.43% Do institutionals and insiders have more ownership in ABBV or INCY? 70.2% of AbbVie shares are held by institutional investors. Comparatively, 97.0% of Incyte shares are held by institutional investors. 0.1% of AbbVie shares are held by company insiders. Comparatively, 17.8% of Incyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryAbbVie beats Incyte on 11 of the 17 factors compared between the two stocks. Get Incyte News Delivered to You Automatically Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INCY vs. The Competition Export to ExcelMetricIncyteMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.67B$3.37B$6.10B$10.65BDividend YieldN/A2.29%5.70%4.74%P/E Ratio19.4021.7185.5527.59Price / Sales3.93477.39622.26138.47Price / Cash157.5747.6737.7861.77Price / Book4.7710.1413.136.76Net Income$32.62M-$52.31M$3.30B$275.88M7 Day Performance-1.52%6.72%5.27%3.71%1 Month Performance-1.36%15.01%9.93%10.21%1 Year Performance29.88%29.34%87.76%35.85% Incyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INCYIncyte4.5031 of 5 stars$85.38-2.1%$83.64-2.0%+32.6%$16.67B$4.24B19.402,617Analyst ForecastABBVAbbVie4.6253 of 5 stars$222.93+1.1%$223.45+0.2%+20.6%$389.72B$56.33B106.1655,000Trending NewsAnalyst ForecastREGNRegeneron Pharmaceuticals4.7488 of 5 stars$560.75-0.6%$817.67+45.8%-41.4%$59.77B$14.20B14.1315,106Positive NewsAnalyst ForecastALNYAlnylam Pharmaceuticals4.0578 of 5 stars$447.49+0.2%$439.58-1.8%+72.3%$58.51B$2.25B-181.172,230Analyst ForecastBIIBBiogen4.5817 of 5 stars$138.52+0.8%$182.04+31.4%-17.0%$20.14B$9.68B13.247,605Analyst ForecastAnalyst RevisionUTHRUnited Therapeutics4.3269 of 5 stars$424.31-1.9%$449.57+6.0%+30.6%$19.52B$2.88B16.561,305Analyst ForecastInsider TradeNBIXNeurocrine Biosciences4.7523 of 5 stars$140.27-1.2%$161.89+15.4%+22.1%$14.08B$2.36B41.501,800Analyst ForecastEXELExelixis4.8765 of 5 stars$40.57+3.9%$44.42+9.5%+50.6%$10.51B$2.17B19.501,147Positive NewsAnalyst ForecastBMRNBioMarin Pharmaceutical4.9493 of 5 stars$54.02+0.3%$92.60+71.4%-20.7%$10.34B$2.85B16.033,040Analyst ForecastIONSIonis Pharmaceuticals3.566 of 5 stars$64.15+0.1%$73.88+15.2%+82.1%$10.22B$705M-34.861,069Analyst ForecastEXASExact Sciences4.4391 of 5 stars$53.38-0.4%$68.05+27.5%-16.6%$10.14B$2.76B-9.837,000News CoveragePositive NewsAnalyst Upgrade Related Companies and Tools Related Companies AbbVie Competitors Regeneron Pharmaceuticals Competitors Alnylam Pharmaceuticals Competitors Biogen Competitors United Therapeutics Competitors Neurocrine Biosciences Competitors Exelixis Competitors BioMarin Pharmaceutical Competitors Ionis Pharmaceuticals Competitors Exact Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INCY) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredGOLD ALERTGold has shattered records, soaring past $3,800 an ounce... But Stansberry Senior Partner Dr. David "Doc" E...Stansberry Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
